IL-2-IgG2b fusion protein suppresses murine contact hypersensitivity in vivo

René Rückert, Katja Brandt, Udo Hofmann, Silvia Bulfone-Paus, Ralf Paus

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Interleukin-15 shares several functional properties with interleukin-2, and signals through the β and γ chain of the interleukin-2 receptor as well as through its own high affinity α chain. In agreement with the concept that interleukin-2 plays a key role in type IV immune responses, we have recently shown that an IL-2-IgG2b fusion protein potently suppresses Th1-type delayed type hypersensitivity reaction and Th2-type allergic sensitization in mice. We have now compared the in vivo effects of IL-2-IgG2b fusion protein with those of IL-15-IgG2b fusion protein in a murine model of Th1-type contact hypersensitivity reaction. Daily systemic injections of IL-2-IgG2b fusion protein during the sensitization phase or application of IL-2-IgG2b fusion protein just 2 h before and 10 h after antigen challenge significantly inhibited the contact hypersensitivity ear swelling response, and this without any overt signs of associated toxicity. Even local injection of IL-2-IgG2b fusion protein into the earlobe around the time of antigen challenge inhibited the ear swelling reaction significantly. In contrast, neither systemic nor local injection of the IL-15-IgG2b fusion protein modulated the contact hypersensitivity reaction significantly. IL-2-IgG2b but not IL-15-IgG2b fusion protein reduced migration of antigen-presenting cells from the skin to local lymph nodes, inhibited the expression of CD80 and CD86, and induced a significant higher number of CD4+CD25+ T cells. Therefore, the IL-2-IgGb fusion protein offers a powerful tool for suppressing and/or preventing T-cell-mediated hypersensitivity reaction in vivo.

Original languageEnglish (US)
Pages (from-to)370-376
Number of pages7
JournalJournal of Investigative Dermatology
Volume119
Issue number2
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Contact Dermatitis
Interleukin-2
Fusion reactions
Interleukin-15
Proteins
T-cells
Injections
Ear
Swelling
Hypersensitivity
T-Lymphocytes
Antigens
Interleukin-2 Receptors
Delayed Hypersensitivity
Antigen-Presenting Cells
Toxicity
Skin
Lymph Nodes

Keywords

  • Contact hypersensitivity
  • Fusion protein
  • Interleukin-15
  • Interleukin-2
  • Th1

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

IL-2-IgG2b fusion protein suppresses murine contact hypersensitivity in vivo. / Rückert, René; Brandt, Katja; Hofmann, Udo; Bulfone-Paus, Silvia; Paus, Ralf.

In: Journal of Investigative Dermatology, Vol. 119, No. 2, 01.01.2002, p. 370-376.

Research output: Contribution to journalArticle

Rückert, René ; Brandt, Katja ; Hofmann, Udo ; Bulfone-Paus, Silvia ; Paus, Ralf. / IL-2-IgG2b fusion protein suppresses murine contact hypersensitivity in vivo. In: Journal of Investigative Dermatology. 2002 ; Vol. 119, No. 2. pp. 370-376.
@article{51f169e5f30b4185aeabff10319c2a26,
title = "IL-2-IgG2b fusion protein suppresses murine contact hypersensitivity in vivo",
abstract = "Interleukin-15 shares several functional properties with interleukin-2, and signals through the β and γ chain of the interleukin-2 receptor as well as through its own high affinity α chain. In agreement with the concept that interleukin-2 plays a key role in type IV immune responses, we have recently shown that an IL-2-IgG2b fusion protein potently suppresses Th1-type delayed type hypersensitivity reaction and Th2-type allergic sensitization in mice. We have now compared the in vivo effects of IL-2-IgG2b fusion protein with those of IL-15-IgG2b fusion protein in a murine model of Th1-type contact hypersensitivity reaction. Daily systemic injections of IL-2-IgG2b fusion protein during the sensitization phase or application of IL-2-IgG2b fusion protein just 2 h before and 10 h after antigen challenge significantly inhibited the contact hypersensitivity ear swelling response, and this without any overt signs of associated toxicity. Even local injection of IL-2-IgG2b fusion protein into the earlobe around the time of antigen challenge inhibited the ear swelling reaction significantly. In contrast, neither systemic nor local injection of the IL-15-IgG2b fusion protein modulated the contact hypersensitivity reaction significantly. IL-2-IgG2b but not IL-15-IgG2b fusion protein reduced migration of antigen-presenting cells from the skin to local lymph nodes, inhibited the expression of CD80 and CD86, and induced a significant higher number of CD4+CD25+ T cells. Therefore, the IL-2-IgGb fusion protein offers a powerful tool for suppressing and/or preventing T-cell-mediated hypersensitivity reaction in vivo.",
keywords = "Contact hypersensitivity, Fusion protein, Interleukin-15, Interleukin-2, Th1",
author = "Ren{\'e} R{\"u}ckert and Katja Brandt and Udo Hofmann and Silvia Bulfone-Paus and Ralf Paus",
year = "2002",
month = "1",
day = "1",
doi = "10.1046/j.1523-1747.2002.01849.x",
language = "English (US)",
volume = "119",
pages = "370--376",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - IL-2-IgG2b fusion protein suppresses murine contact hypersensitivity in vivo

AU - Rückert, René

AU - Brandt, Katja

AU - Hofmann, Udo

AU - Bulfone-Paus, Silvia

AU - Paus, Ralf

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Interleukin-15 shares several functional properties with interleukin-2, and signals through the β and γ chain of the interleukin-2 receptor as well as through its own high affinity α chain. In agreement with the concept that interleukin-2 plays a key role in type IV immune responses, we have recently shown that an IL-2-IgG2b fusion protein potently suppresses Th1-type delayed type hypersensitivity reaction and Th2-type allergic sensitization in mice. We have now compared the in vivo effects of IL-2-IgG2b fusion protein with those of IL-15-IgG2b fusion protein in a murine model of Th1-type contact hypersensitivity reaction. Daily systemic injections of IL-2-IgG2b fusion protein during the sensitization phase or application of IL-2-IgG2b fusion protein just 2 h before and 10 h after antigen challenge significantly inhibited the contact hypersensitivity ear swelling response, and this without any overt signs of associated toxicity. Even local injection of IL-2-IgG2b fusion protein into the earlobe around the time of antigen challenge inhibited the ear swelling reaction significantly. In contrast, neither systemic nor local injection of the IL-15-IgG2b fusion protein modulated the contact hypersensitivity reaction significantly. IL-2-IgG2b but not IL-15-IgG2b fusion protein reduced migration of antigen-presenting cells from the skin to local lymph nodes, inhibited the expression of CD80 and CD86, and induced a significant higher number of CD4+CD25+ T cells. Therefore, the IL-2-IgGb fusion protein offers a powerful tool for suppressing and/or preventing T-cell-mediated hypersensitivity reaction in vivo.

AB - Interleukin-15 shares several functional properties with interleukin-2, and signals through the β and γ chain of the interleukin-2 receptor as well as through its own high affinity α chain. In agreement with the concept that interleukin-2 plays a key role in type IV immune responses, we have recently shown that an IL-2-IgG2b fusion protein potently suppresses Th1-type delayed type hypersensitivity reaction and Th2-type allergic sensitization in mice. We have now compared the in vivo effects of IL-2-IgG2b fusion protein with those of IL-15-IgG2b fusion protein in a murine model of Th1-type contact hypersensitivity reaction. Daily systemic injections of IL-2-IgG2b fusion protein during the sensitization phase or application of IL-2-IgG2b fusion protein just 2 h before and 10 h after antigen challenge significantly inhibited the contact hypersensitivity ear swelling response, and this without any overt signs of associated toxicity. Even local injection of IL-2-IgG2b fusion protein into the earlobe around the time of antigen challenge inhibited the ear swelling reaction significantly. In contrast, neither systemic nor local injection of the IL-15-IgG2b fusion protein modulated the contact hypersensitivity reaction significantly. IL-2-IgG2b but not IL-15-IgG2b fusion protein reduced migration of antigen-presenting cells from the skin to local lymph nodes, inhibited the expression of CD80 and CD86, and induced a significant higher number of CD4+CD25+ T cells. Therefore, the IL-2-IgGb fusion protein offers a powerful tool for suppressing and/or preventing T-cell-mediated hypersensitivity reaction in vivo.

KW - Contact hypersensitivity

KW - Fusion protein

KW - Interleukin-15

KW - Interleukin-2

KW - Th1

UR - http://www.scopus.com/inward/record.url?scp=0036041391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036041391&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1747.2002.01849.x

DO - 10.1046/j.1523-1747.2002.01849.x

M3 - Article

C2 - 12190859

AN - SCOPUS:0036041391

VL - 119

SP - 370

EP - 376

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 2

ER -